AARD Earnings Preview: Options Price a ±79.3% Move
· The NYC Memo · AARD reports 2026-11-12
Aardvark Therapeutics, Inc. reports November 12, 2026. The November 20, 2026 straddle implies ±79.25% against a 6.73% average reaction, with dealers long gamma and max pain at $5.
Live updates
Nov 12 — Ahead of earnings on November 12, 2026, AARD rose from $1.37 to $1.59 as its implied move fell from ±89.78% to ±79.25%, implying that options markets anticipate a narrower post-earnings price swing.
Nov 11 — Ahead of earnings on November 12, 2026, the AARD implied move contracted from ±91.11% to ±89.78% as at-the-money implied volatility fell from 660.0% to 595.8%, implying moderating expectations for post-announcement price swings around the 1.37 spot price.
Nov 10 — Ahead of November 12, 2026 earnings, AARD rose from $1.17 to $1.35 while at-the-money implied volatility increased from 461.7% to 660.0%, shifting the implied move from ±105.13% to ±91.11% to price in an expected post-earnings swing of ±91.11%.
Aardvark Therapeutics, Inc. reports Q3 2026 results on November 12, 2026, with spot at $1.59. The options market prices substantial movement, with the November 20, 2026 straddle at $1.26 and implied volatility at 379.0%. That pricing implies a move of 79.25%, defining an implied range of $0.33 to $2.85. This swing exceeds the average realised reaction of 6.73% across 6 prints, where shares finished higher 2 times and lower 4 times.
The chain shows a dealer lean of long gamma, with max pain at $5 and put call open interest at 0.43. This long gamma posture means dealer hedging should cushion directional moves into the print, actively dampening tape volatility.
What the market will be watching
The desk enters the Aardvark Therapeutics earnings release focused on underlying therapy demand and clinical pipeline advancements. Investors will scrutinize clinical development expenses and research spending to gauge operating cost pressures. Management commentary regarding commercial adoption trends and pipeline milestones will shape near-term sentiment. The market will also evaluate updated guidance for the remainder of the year to assess operational runway and projected capital needs. Any regulatory feedback or timeline adjustments for lead drug candidates will dictate post-earnings volatility.
What the options market is pricing
| Measure | Level |
|---|---|
| November 12, 2026 | |
| Expiry used | November 20, 2026 (8 days out) |
| Spot | $1.59 |
| ATM straddle | $1.26 |
| Implied move | ±79.25% ($0.33 to $2.85) |
| ATM implied vol | 379.0% |
| Put/call open interest | 0.43 |
| Max pain | $5 |
| Net dealer gamma | +$0.00mn per 1% move, LONG GAMMA |
| Heaviest call strike above spot | $2.5 (303 contracts) |
| Street EPS estimate | $-0.74 |
| Street revenue estimate | $0.00bn |
Dealers sit long gamma into the print, which means their hedging leans against the move and tends to compress AARD between catalysts. That damping disappears the moment the number crosses the tape.
How the stock has reacted before
| Report | Next-day move |
|---|---|
| Q2 2026, Aug 11 | -8.62% |
| Q1 2026, May 7 | -4.92% |
| Q4 2025, Mar 23 | -7.26% |
| Q3 2025, Nov 13 | -8.66% |
| Q2 2025, Aug 13 | +0.54% |
| Q4 2024, Mar 31 | +10.39% |
Across the last 6 prints the average absolute reaction is 6.73%, with 2 higher and 4 lower. The best was +10.39% and the worst -8.66%. Options are asking ±79.25%, which is 72.52 points richer than the realised average, the premium seller's case.
Where the stock is trading
| Measure | Level |
|---|---|
| Spot | $1.59 |
| 52-week range | $0.93 to $16.60 |
| Position in that range | 4% |
| From the 52-week high | -90.4% |
| From the 52-week low | +71.0% |
| Past week | +26.2% |
| Past month | -60.6% |
| Past three months | -75.2% |
| 50-day average | $3.94 |
| 200-day average | $5.76 |
How the options market is pricing it
The November 20, 2026 straddle marks $0.33 to $2.85 as the range the options market is paying for into the print, with ATM implied vol at 379% set to drain the morning after. A reaction inside that band hands the edge to premium sellers; a break outside it rewards premium buyers. Historically AARD has moved 6.73% on earnings against the ±79.25% now implied, so the market is pricing this print richer than the recent average. Which side of that trade is right depends on the number, the guidance and where positioning unwinds.
Read the mechanics behind the crush in our earnings volatility guide, and pull the live memo for AARD before the print.
Data as of November 12, 2026 from the live option chain, exchange price history and SEC-dated earnings reactions. This is research, not investment advice.
Related: AARD options memo
More earnings previews
- ABUS Earnings Preview: Options Price a ±10.3% Move
- ACOG Earnings Preview: Options Price a ±8.6% Move
- AIRJ Earnings Preview: Options Price a ±29.1% Move
- ABEO Earnings Preview: Options Price a ±126.8% Move
- ABSI Earnings Preview: Options Price a ±17.6% Move
- AGRO Earnings Preview: Options Price a ±17.2% Move